Related Experiment Video
Updated: Jun 23, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
Europe combating cancer: the European Union's commitment to cancer research in the 6th Framework Programme
Stefan Jungbluth1, Olaf Kelm, Jan-Willem van de Loo
1European Commission, Directorate General for Research, Health Research, B-1049 Brussels, Belgium.
Abstract:
As one of the major health issues in Europe, cancer was a research priority in the 6th Framework Programme (2002-2006). About 485 million euros were devoted to this theme, which allowed funding of 108 multidisciplinary transnational projects. A significant part of them was large-scale initiatives addressing complex issues through a broad combination of competences. All major types of cancer were covered, as well as the three dimensions such as prevention, diagnostic and treatment, with a particular emphasis on translational research aiming at bringing basic knowledge on medical practice. This approach will be continued in the 7th Framework Programme (2007-2013), together with a strengthened effort to improve the coordination of European cancer research, which is fragmented and in which EU action represents only a small part. EU cancer research will also be addressed within the reinforced efforts in the areas of pharmaceutical and technological developments as well as common aetiological mechanisms of diseases that the 7th Framework Programme will undertake.
Related Concept Videos
Cancer Prevention
Some...
Cancer Prevention
Some...
Treatment Resistent Cancers
Treatment Resistant Cancers
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

